AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
A phase 3 trial of Ivonescimab, Paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Akeso, now recruiting.
Overview
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer is a phase 3 interventional study registered as NCT06767527 by Akeso, with 416 participants planned, started 2025-02-07 and due to reach its primary completion in 2026-12. Interventions recorded: AK112, Nab-paclitaxel, Placebo. Conditions listed: Triple-Negative Breast Cancer (TNBC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor
Shares Ivonescimab, Akeso.
- TrialAK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Shares Ivonescimab, Akeso, Paclitaxel / nab-paclitaxel.
- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Ivonescimab, Akeso, Paclitaxel / nab-paclitaxel.
- TrialA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Shares Ivonescimab, Akeso.
- TrialCombination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
Shares Ivonescimab, Akeso.
- TrialAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Shares Ivonescimab, Akeso.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso.